Biocryst Pharma sells European activities for rare disease drugs in an agreement of $ 250 million

Biocryst Pharmaceuticals sells European rights and assets for its best product for 250 million dollars, in cash that the developer of rare drugs will use to repay the debt.

The buyer is privately gentili. Beyond the initial payment, the terms of the agreement announced on Friday the triangle research biocrystal worker, in North Carolina, online for $ 14 million in payments of milestones associated with sales of Central and Eastern Medicines, Orladeyo.

Orladeyo was developed for the hereditary edema of the angiodema (HAE), a hereditary disorder which leads to inflated attacks in various parts of the body. These attacks can become fatal when they close a patient’s respiratory tract. Biocristalon drug is an oral inhibitor of small Kallikrein molecules, a protein that plays a role in swelling and inflammation that develops in HAE attacks. The FDA approved the former daily pill of the biocristain in 2020 for the prevention of HAE attacks in adults and children aged 12 and over. He won the marketing authorization in Europe the following year.

Neopharmed Gentili has medication partnerships with Merck -based Diabetes and Merck Spinoff Organon, covering several therapeutic areas. The pharmaceutical company based in Milan, Italy, also has an alliance with Teva Pharmaceutical on the Drug Duoresp Spiromax asthma. The company said that the landing of European rights on ordeyo widens its activities and gives it a presence in rare diseases.

Biocristal and Neopharmed Genti expect to conclude the agreement by early October. Biocryst said it would use the product to withdraw $ 249 million from remaining debts, eliminating around $ 70 million in future interest payments. The sale of the European company will also save biocrystals of approximately $ 50 million in annual expenses. The Company is expecting it to end 2027 with around $ 700 million in cash, an increase of $ 400 million compared to its 2027 cash forecasts. In a prepared declaration, CEO Jon Stonehouse has said that the increased Biocristal profitability puts the company in a stronger position to continue to develop the ordeseyo and drug pipeline. The company can also explore external opportunities.

ORLADEYO is the main source of income from BIOCRYST, representing $ 437.6 million in sales in 2024, according to the company’s annual report. Of this total, $ 385.9 million was in the United States, the next growth opportunity for Orladeyo reached younger children. A formulation of oral granules of the medication is during a priority examination of the FDA for the prevention of HAE attacks in children from 2 to 11 years old; A regulatory decision is expected by September 12. Takeda Pharmaceutical Kallikrein inhibitor, Takhzyro, is also approved for the prevention of HAE in young children, but is administered by injection. Biocristal holds global rights on the oral formulation of goldsmith granules, which would offer young children an easier dosage option.

There are other HAE drugs available for patients aged 12 and over, but they are all administered in the form of injections. The drug from the Ruconest Pharming group is a Estérase C1 inhibitor. Two weeks ago, CSL Behring landed FDA approval for Andembry, an inhibitor of a plasma protein called factor XIIA.

Kalvista Pharmaceuticals has an oral inhibitor from Kallikrein once a day, Sebetrastat, currently under the FDA review. Earlier this month, Kalvista revealed that the FDA said that it would not respect the target date of June 17 for a regulatory decision. Kalvista also studies this medication for use in children from 2 to 11 years old.

Photo: Getty Images